Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2015-01-09
2019-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of ExSpiron™ Measurements Derived Without Patient Specific Calibration
NCT02690298
Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring
NCT04017702
Postoperative Respiratory and Activity Monitoring
NCT06239831
Respiratory Volume Measure Using ExSpiron 1Xi
NCT02998294
Non-invasive Respiratory Monitoring During SBT
NCT05295186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypotheses
Primary:
Low minute ventilation (LMV) defined as sustained LMV\<40% minute ventilation predicted (MVPRED) based on IBW following opioid administration correlates with adverse clinical outcomes in PACU or on the floor including:
* O2 desaturation, atelectasis, respiratory status requiring advanced monitoring
* respiratory interventions such as O2 administration, continuous positive airway pressure CPAP, BiPAP,
* incidence of ICU transfer and/or increase in PACU and/or general hospital floor (GHF) length of stay (LOS).
Secondary:
* 1\. Decreased MV defined as sustained MV\<80% MVPRED based on IBW before opioid administration correlates with adverse clinical outcomes as defined above.
* 2\. Patients with decreased MV prior to opioid administration will be more likely to develop LMV after standard opioid administration compared to patients with normal MV defined as MV ≥ 81% MVPRED based on ideal body weight (IBW)
Rationale Continuous respiratory monitoring using the ExSpiron System will be particularly beneficial to patients in the post-anesthesia environment. Assessment and management of respiratory function and early intervention when indicated is a multifaceted, complex task often complicated by the lack of a cohesive and continuous monitoring system to guide clinical decisions. The ExSpiron system is designed for these patients and is intended to address some of the limitations of the current generation of hospital monitors and to provide healthcare providers with continuous real-time data regarding the patient's respiratory status. Recent data has shown that stratification of patients based on the RVM's MV as % of predicted MV (MVPRED), prior to opioid dosing has made it possible to identify patients who are at risk for further decreases in MV and opioid-induced respiratory depression (OIRD).
1. In the spontaneously breathing, non-ventilated patient, current monitoring devices do not provide continuous, objective non-invasive, continuous real time information of the important respiratory parameters TV, MV \& RR.
2. Current monitoring of non-intubated patients mostly relies on subjective clinical assessment, oximetry data, and rarely end-tidal carbon dioxide CO2 measurements. In appropriate clinical settings, the ExSpiron system can provide direct quantitative measure of ventilation parameters for use in clinical assessment and trend prediction as well as response to medications and other interventions to allow for more efficient clinical decision making.
3. Current technologies do not provide for a continuity of care between the PACU and the general hospital floor.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Invasive Respiratory Volume Monitor
The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Respiratory Motion, Inc.
INDUSTRY
Tufts Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iwona Bonney, PhD
Role: PRINCIPAL_INVESTIGATOR
Tufts Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tufts Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11544
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.